Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma
31 Oct 2024
Quebec City, Canada & Sydney, Australia, October 31 2024 - Feldan Therapeutics (Feldan), a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, has announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC).